Developing a new treatment to improve muscle recovery after hip fractures in older adults
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
This study is testing a new pill called RT-002 to see if it can help older adults heal better and regain strength after a hip fracture, with the hope of making their recovery easier and improving their overall quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ridgeline Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Houston, UNITED STATES) |
| Project ID | NIH-11080486 on NIH RePORTER |
What this research studies
This research focuses on RT-002, a novel oral therapeutic designed to help older adults recover more effectively from hip fractures. The study involves preclinical testing in various animal models to assess the safety and effectiveness of the treatment. By examining how RT-002 interacts with aging muscle stem cells, the researchers aim to enhance muscle strength and function post-injury. The ultimate goal is to improve the quality of life for patients who have experienced traumatic hip injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 65 and older who have suffered a hip fracture.
Not a fit: Patients under 65 years of age or those without a history of hip fractures may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance recovery and quality of life for older adults after hip fractures.
How similar studies have performed: Previous research has shown promise in developing therapies for muscle recovery in older adults, indicating potential for success with this approach.
Where this research is happening
Houston, UNITED STATES
- Ridgeline Therapeutics, LLC — Houston, United States (Active)
Researchers
- Principal investigator: Neelakantan, Harshini — Ridgeline Therapeutics, LLC
- Study coordinator: Neelakantan, Harshini
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.